Can Caplyta (lumateperone) be used in patients with tardive dyskinesia (TD), and what is the recommended dosing?

Caplyta and Tardive Dyskinesia

Caplyta (lumateperone) can be used in patients with schizophrenia who have tardive dyskinesia, but like all antipsychotics, it carries a risk of causing or worsening TD and should be prescribed at the lowest effective dose (42 mg once daily) with regular monitoring for movement disorders.

Understanding the Risk-Benefit Context

The FDA label for Caplyta explicitly warns that tardive dyskinesia may develop in patients treated with antipsychotic drugs, including lumateperone 1. The risk increases with duration of treatment and cumulative dose, and the syndrome can develop even after brief treatment periods at low doses. Importantly, TD may persist even after discontinuation of the antipsychotic.

Clinical Decision Algorithm

If TD is Already Present:

1. Assess severity and impact on quality of life

   • If TD is mild and patient's psychosis is well-controlled on current antipsychotic: Consider whether switching to Caplyta offers meaningful benefit
   • If TD is moderate to severe/disabling: The APA recommends treatment with a VMAT2 inhibitor (valbenazine or deutetrabenazine) as first-line therapy 2

2. If switching to Caplyta is warranted:

   • The general principle is to switch to an atypical antipsychotic when TD develops 3
   • Lumateperone appears to have a lower risk of extrapyramidal symptoms compared to typical antipsychotics and even some atypicals like risperidone 4
   • Use the standard dose: 42 mg once daily (no titration required)
   • Document baseline abnormal movements using the Abnormal Involuntary Movement Scale (AIMS) 3

If No TD is Present:

1. Prevention strategy:
   • Obtain baseline AIMS assessment before starting Caplyta 3
   • Monitor for dyskinesias every 3-6 months during treatment 3
   • Use the lowest effective dose (42 mg daily for schizophrenia)
   • Periodically reassess the need for continued treatment 1

Key Advantages of Lumateperone

Research suggests lumateperone has a favorable movement disorder profile compared to older antipsychotics:

• Pooled studies showed EPS-related adverse events were less frequent with lumateperone 42 mg compared to risperidone 4
• The drug was not associated with significant EPS or dystonia in clinical trials 4
• Its novel mechanism (simultaneous modulation of serotonin, dopamine, and glutamate) may contribute to lower TD risk 5

Critical Monitoring Requirements

If TD emerges while on Caplyta:

• Drug discontinuation should be considered 1
• However, some patients may require continued treatment with Caplyta despite TD presence if discontinuation would precipitate severe psychotic relapse 3
• In such cases, add a VMAT2 inhibitor for moderate-to-severe TD 2

Important Caveats

• The FDA label states it's impossible to predict which patients will develop TD 1
• Elderly patients, especially elderly women, are at highest risk 1
• Recent data shows females and patients with bipolar disorder may have different adverse event profiles with lumateperone, including nervous system disorders 6
• Antipsychotic treatment itself may mask TD symptoms, making the underlying process harder to detect 1

Dosing Specifics

Standard dose: 42 mg once daily with food

• No titration required
• No dose adjustment needed for mild-moderate renal or hepatic impairment
• Avoid in severe hepatic impairment

The evidence supports using Caplyta in patients with TD when the benefits of treating schizophrenia outweigh the risks, but vigilant monitoring and consideration of VMAT2 inhibitors for established TD is essential 2, 1.